Supplemental Digital Content 3 (Table). Pipeline Molecules in Development Targeting the Angiopoietin/Tie2 Pathway for Retinal Vascular Diseases

|  |  |  |  |
| --- | --- | --- | --- |
| **Molecule** | **Target** | **Company** | **Status** |
| BI 836880 | Anti-VEGF/Ang-2 nanobody | Boehringer Ingelheim, Ablynx | Phase 1 trial in nAMD commenced June 27, 2019 (NCT03861234) |
| ARP-1536 | Anti–VE-PTP antibody | Aerpio Pharmaceuticals, Inc. | Pipeline/preclinical for nAMD and DME |
| AMSB10386 | Bispecific aptamer targeting VEGF and Ang-2 | Aptitude Medical Systems | Pipeline/preclinical |
| AXT10787 | Collagen IV–derived peptide that inhibits VEGF and activates Tie2 | AsclepiX | Pipeline/preclinical for nAMD and DME; scheduled for phase 1/2 commencing in 2020 |
| AAV2.COMP-Ang161, 69 | Adenovirus-delivered Ang-1 | NA | Preclinical tool only to date |

Ang-2, angiopoietin-2; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; Tie, tyrosine kinase with immunoglobulin-like and endothelial growth factor–like domains; VEGF, vascular endothelial growth factor; VE-PTP, vascular endothelial protein tyrosine phosphatase.